Mycophenolate mofetil in paediatric autoimmune or immune‐mediated diseases of the central nervous system: clinical experience and recommendations-Reference-Cited by-同舟云学术

Mycophenolate mofetil in paediatric autoimmune or immune‐mediated diseases of the central nervous system: clinical experience and recommendations

Published:2018-09-17 Issue:4 Volume:61 Page:458-468
ISSN:0012-1622
Container-title:Developmental Medicine & Child Neurology
language:en
Short-container-title:Dev Med Child Neurol

Author:

Nosadini Margherita¹²^ORCID,Gadian Jonathan³⁴,Lim Ming³,Sartori Stefano²,Thomas Terrence⁵,Dale Russell C¹^ORCID

Affiliation:

1. Neuroimmunology Group, Institute for Neuroscience and Muscle Research Kids Research at the Children's Hospital at Westmead University of Sydney Westmead Australia

2. Paediatric Neurology and Neurophysiology Unit Department of Women's and Children's Health University Hospital of Padua Padua Italy

3. Children's Neurosciences Centre Guy's & St Thomas’ NHS Foundation Trust Kings Health Partners Academic Health Science Centre Evelina London Children's Hospital London UK

4. Faculty of Life Sciences and Medicine King's College London London UK

5. KK Women's & Children's Hospital Singapore

Publisher

Wiley

Subject

Clinical Neurology,Developmental Neuroscience,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dmcn.14020

Reference40 articles.

1. Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms

2. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy

3. Mycophenolate mofetil for myasthenia gravis: a clear and present controversy